Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders

Pharmacogenomics

Volumn 7, Issue 7, 2006, Pages 1095-1107

  Griffin, Julian L ^a   Nicholls, Andrew W ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Metabolic profiling; Metabonomics; Obesity; Systems biology; Type II diabetes

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; 1,2 DIMETHYLHYDRAZINE; ADENOSINE; CARBON TETRACHLORIDE; DIMETHYLGLYCINE; GALACTOSAMINE; GLUCOSE; HYDRAZINE; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYROGLUTAMIC ACID; ROSIGLITAZONE; TRIMETHYLAMINE OXIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DEVELOPMENTAL STAGE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; FATTY LIVER; FUNCTIONAL GENOMICS; GAS CHROMATOGRAPHY; HUMAN; INBORN ERROR OF METABOLISM; INFRARED SPECTROSCOPY; LIPID COMPOSITION; LIPODYSTROPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC SYNDROME X; METABOLISM; METABOLITE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SYSTEMS BIOLOGY; TOXICITY TESTING;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY LIVER; GENOMICS; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; OBESITY; REFERENCE VALUES; RESEARCH DESIGN;

ANIMALIA;

EID: 33750431077     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.7.1095     Document Type: Review

References (67)

1. Oliver SG, Winson MK, Kell DB, Baganz F: Systematic functional analysis of the yeast genome. Trends Biotechnol. 16, 373-378 (1998).
2. Oliver SG: From genomes to systems: the path with yeast. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 361(1467), 477-482 (2006).
3. Bino RJ, Hall RD, Fiehn O et al.: Potential of metabolomics as a functional genomics tool. Trends Plant Sci. 9(9), 418-425 (2004).
4. Nicholson JK, Lindon JC, Holmes E: Metabonomics. Xenobiotica 29(11), 1181-1189 (1998).
5. Nicholson JK, Holmes E, Wilson ID: Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3(5), 431-438 (2005).
6. Raamsdonk LM, Teusink B, Broadhurst D et al.: A functional genomics strategy that uses metabolome data to reveal the phenotypye of silent mutations. Nat. Biotechnol. 19, 45-50 (2001).
7. Allen J, Davey HM, Broadhurst D et al.: High-throughput classification of yeast mutants for functional genomics using metabolic footprinting. Nat. Biotechnol. 21, 692-696 (2003).
8. Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L: Metabolite profiling for plant functional genomics. Nat. Biotechnol. 18, 1157-1161 (2000).
9. Jones GL, Sang E, Goddard C et al.: A functional analysis of mouse models of cardiac disease through metabolic profiling. J. Biol. Chem. 280(9), 7530-7539 (2005).
10. Ismail AA, Gill GV: The epidemiology of Type 2 diabetes and its current measurement. Baillieres Best Pract. Res. Clin. Endocrinol, Metab. 3(2), 197-220 (1999).
11. Kopelman PG: Obesity as a medical problem. Nature 404, 635-643 (2000).
12. Brown SC, Kruppa G, Dasseux JL: Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom. Rev. 24(2), 223-231 (2005).
13. Griffin JL, Shockcor JP: Metabolic profiles of cancer cells. Nat. Rev. Cancer 4(7), 551-561 (2004).
14. Beckwith-Hall BM, Nicholson JK, Nicholls AW et al. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol. 11, 260-272 (1998).
15. 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed. 11 (4-5), 235-244 (1998).
16. Mortishire-Smith RJ, Skiles GL, Lawrence JW et al.: Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 17(2), 165-173 (2004).
17. Griffin JL, Sang E, Evens T, Davies K, Clarke K: Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy. FEBS Letts. 530(1-3), 109-116 (2002).
18. 1H NMR spectroscopy using a 1mm Microlitre probe. Analyst 127(5), 582-584 (2002).
19. Khandelwal P, Beyer CE, Lin Q, Schechter LE, Bach AC: 2nd. Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach. Anal. Chem. 76(14), 4123-4127 (2004).
20. 13C NMR spectroscopy of urine for metabonomic studies. Anal. Chem. 74, 4588-4593 (2002).
21. Bailey NJ, Oven M, Holmes E, Nicholson JK, Zenk MH: Metabolomic analysis of the consequences of cadmium exposure in Silene cucubalus cell cultures via 1H NMR spectroscopy and chemometrics. Phytochemistry 62, 851-858 (2003).
22. 1H-NMR spectroscopy and chemometrics. Planta Med. 68, 734-738 (2002).
23. Vaidyanatharr S, Gaskell S, Goodacre R: Matrix-suppressed laser desorption/ionisation mass spectrometry and its suitability for metabolome analyses. Rapid Commun. Mass Spectrom. 20(8), 1192-1198 (2006).
24. Schwudke D, Oegema J, Burton L et al.: Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition. Anal. Chem. 78, 585-595 (2006).
25. Shellie RA, Welthagen W, Zrostlikova J et al.: Statistical methods for comparing comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry results: metabolomic analysis of mouse tissue extracts. J. Chromatogr. A. 1086(1) 83-90 (2005).
26. Gullberg J, Jonsson P, Nordstrom A, Sjostrom M, Moritz T: Design of experiments: an efficient strategy to identify factors influencing extraction and derivatization of Arabidopsis thaliana samples in metabolomic studies with gas chromatography/mass spectrometry. Anal. Biochem. 331, 283-295 (2004).
27. A J, Trygg J, Gullberg J et al.: Extraction and GC/MS Anaiysis of the human blood plasma metabolome Anal. Chem. 77, 8086-8094 (2005).
28. 1H-NMR-based urine metabolic profiles of male Wistar Han rats: implications for biomarker discovery. Biomarkers. 9(2), 156-179 (2004).
29. Valafar F: Pattern recognition techniques in microarray data analysis: a survey. Ann. NY Acad, Sci. 980, 41-64 (2002).
30. Lindon JC, Kenn HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK: The Consortium for Metabonomic Toxicology (COMET), aims, activities and achievements. Pharmacogenomics 6(7), 691-699 (2005).
31. Holmes E, Antti H: Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analystl 27(12), 1549-1557 (2002).
32. Foxall PJ, Bewley S, Neild GH, Rodeck CH, Nicholson JK: Analysis of fetal and neonatal urine using proton nuclear magnetic resonance spectroscopy. Arch. Dis. Child. Fetal Neonatal Ed. 73(3), F153-F157 (1995).
33. Ghauri FY, Parkes HG, Nicholson JK, Wilson ID, Brenton DP: Asymptomatic 5-oxoprolinuria detected by proton magnetic resonance spectroscopy Clin. Chem. 39(6), 1341 (1993).
34. Holmes E, Nicholls AW, Lindon JC et al.: Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem, Res. Toxicol. 13(6) 471-478 (2000).
35. Nicholls AW, Holmes E, Lindon JC et al. Metabonomic investigations into hydrazine toxicity in the rat: induction of 2-aminoacidipic acid. Chem. Res. Toxicol. 14(8), 975-987 (2001).
36. 1H-NMR based urine metabolic profiles of male Wistar Han rats: implications for biomarker discovery. Biomarkers 9(2), 156-179 (2004).
37. Gavaghan McKee CL, Wilson ID, Nicholson JK: Metabolic phenotyping of nude and normal (Alpk:ApfCD, C57BL10J) mice. J. Proteome Res, 5, 378-384 (2006).
38. Stanley EG, Bailey NJC, Bollard ME et al.: Sexual dimorphism in urinary metabolite profiles of Han Wistar rats revealed by nuclear-magnetic-resonance-based metabonomics. Anal. Biochem. 343, 195-202 (2005).
39. Phipps AN, Stewart J, Wright B, Wilson ID: Effect of diet of the urinary excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity. Xenobiotica 28, 527-537 (1998).
40. Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG: Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 87(1), 1-2 (2005).
41. Nicholls AW, Mortishire-Smith RJ, Nicholson JK: NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem. Res. Toxicol. 16(11), 1395-404 (2003).
42. 1H NMR spectroscopic and chemometric studies on endogenous physiological variation in rats. PhD Thesis, University of London, UK (2002).
43. 1H NMR spectroscopy of urine and pattern recognition. Anal. Biochem. 295, 194-202 (2001).
44. 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J. Pharm. Biomed. Anal 33, 1103-1115 (2003).
45. 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal. 36, 841-849 (2004).
46. Kochhar S, Jacobs DM, Ramadan, Z, Berruex F, Fuerholz A, Fay LB: Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal. Biochem. 352, 274-281 (2006).
47. Clayton TA, Lindon JC, Cloarec O et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006).
48. Haselden JN, Nicholls AW: Personalized medicine progresses. Nat. Med. 12(5), 510-511 (2006).
49. Serkova NJ, Jackman M, Brown JL et al.: Metabolic profiling of livers and blood from obese Zucker rats. J. Hepatol. 44, 956-962 (2006).
50. 1H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J. Pharm. Biomed Anal. 38(3), 465-471 (2005).
51. Plumb RS, Granger JH, Stumpf CL et al.: A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst 130(6), 844-849 (2005).
52. Han X, Yang J, Cheng H, Yang K, Abendschein DR, Gross RW: Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry 44(50), 16684-16694 (2005).
53. 1H nuclear magnetic resonance and high performance liquid chromatography. Biomarkers 8(3-4), 240-271 (2003).
54. Xu J, Chang V, Joseph SB et al.: Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 145(3), 1087-1095 (2004).
55. Xu J, Xiao G, Trujillo C et al.: Peroxisome proliferator-activated receptor α (PPARα) influences substrate utilization for hepatic glucose production. J Biol. Chein. 277(52), 50237-50244(2002).
56. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH: Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J. Lipid Res. 43(11), 1809-1817 (2002).
57. Su X, Han X, Yang J et al.: Sequential ordered fatty acid alpha oxidation and δ9 desaturation are major determinants of lipid storage and utilization in differentiating adipocytes. Biochemistry 43(17), 5033-5044 (2004).
58. Corthesy-Theulaz I, den Durmen JT, Ferre P et al.: The impact of biomics technology on nutrition research. Ann. Nutr. Metab. 49, 355-365 (2005).
59. Whitfield PD, German AJ, Noble P-JM: Metabolomics: an emerging post-genomic tool for nutrition. Br. J. Nutr. 92, 549-555 (2004).
60. Wang C, Kong H, Guari Y et al.: Plasma phospholipid metabolic profiling and biomarkers of Type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal. Chem. 77(13), 4108-4116 (2005).
61. Yang J: Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 813(1-2), 53-58 (2004).
62. Clish CB, Davidov E, Oresic M et al.: Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS 8, 3-15 (2004).
63. Mayr M, Chung Y-L, Mayr U et al.: Proteomic and metabolomic analysis of atherosclerotic vessels from Apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress and energy metabolism. Arteriosclerosis, thrombosis and vascular biology. 25, 2135-2142 (2006).
64. 1H-NMR-based metabonomics. Nat. Med. 8(12), 1439-1444 (2002).
65. Kirschenlohr HL, Griffin JL, Clarke SC et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med. 12, 705-10 (2006).
66. Sabatine MS, Emerson L, Morrow DA et al.: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112, 3868-3875 (2005).
67. Griffin JL, Bonney SA, Mann C et al.: An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol Genomics 17(2), 140-149 (2004).